Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084284 | 0.83 | ATM (0.51) | PHGDHALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL27486134 | 0.83 | PHGDH (0.71) | PHGDHHSD17B10ALDH1A1MAPTTSHR | |
| SCHEMBL17131916 | 0.83 | PHGDH (1.00) | PHGDHHSD17B10ALDH1A1MAPTKDM4E | |
| SCHEMBL1020995 | 0.82 | PHGDH (0.66) | PHGDHALDH1A1MAPTGAAMEN1 | |
| SCHEMBL7115197 | 0.81 | LMNA (0.53) | PHGDHALDH1A1MAPTGAATSHR | |
| SCHEMBL3799154 | 0.81 | LMNA (0.53) | PHGDHALDH1A1MAPTGAATSHR | |
| SCHEMBL28258290 | 0.81 | PHGDH (0.56) | PHGDHALDH1A1MAPTGAATSHR | |
| SCHEMBL1020349 | 0.81 | TDP1 (0.62) | PHGDHHSD17B10ALDH1A1MAPTTSHR | |
| Hydrochloric Acid SCHEMBL11538425 | 0.80 | ATM (0.53) | PHGDHALDH1A1MAPTGAATSHR | |
| SCHEMBL1864065 | 0.79 | PHGDH (0.54) | PHGDHALDH1A1MAPTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573915-A | Compounds active against bromodomains | 纽韦卢森公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | disclosed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| CN-102812006-A | New anti-malarial agents | MEDICINES FOR MALARIA VENTURE MMV | 2012-12-05 | — | — | CN | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| CN-102482231-A | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | Bayer Pharma AG | 2012-05-30 | — | — | CN | disclosed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | disclosed |
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | PHGDH 854/4885HSD17B10 3746/4885ALDH1A1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.